Coleen Glessner
Fortuna: 2 M $ al 31/05/2026
Fortuna: 2 M $ al 31/05/2026
Coleen Glessner is currently Executive VP-Quality, Ethics & Compliance at Emergent BioSolutions, Inc. since 2020.
Formerly, Ms. Glessner was Chief Quality Officer & Senior Vice President at Alexion Pharmaceuticals, Inc. from 2017 to 2021 and also served as VP, Head-R&D Quality at Alexion Pharmaceuticals,.
Inc. Education includes an undergraduate degree from the University of Pittsburgh and an MBA from the Massachusetts Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 08/06/2026 | 202.201 ( 0,39 % ) | 2 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Oficial de Cumplimiento | 01/03/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
University of Pittsburgh
University of Pittsburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Emergent BioSolutions, Inc.
Emergent BioSolutions, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.